Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 17th year with record-breaking investor and partner meetings. 6,700+ meetings facilitated in-person and online connections while more than 340 company presentations and 28 panels delivered new value to in-person attendees and helped to shape the 2025 outlook for biotechnology.
The quality of both the speakers and company presentations at this year’s Biotech Showcase conference was absolutely outstanding
Health Technology Insights: Join Pilot’s Annual Heart Month Campaign to Take on Heart Disease and Stroke
“We welcomed more than 3,000 attendees, including 1,026 investors and 86 media representatives this year in a testament to the resilience and ingenuity of the biotech sector,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “With so many company presentations, a robust Seed Showcase, and a new program track, TechBio, Biotech Showcase has become the number one destination of choice for both innovators and private investors.”
New programming this year included the TechBio Showcase, which explored the innovations and trends shaping biotech. Biotech Showcase discussions spanned a broad range of topics, including advancements in cell and gene therapy, enhancing longevity, collaboration opportunities in the Asia Pacific region, trends in biotech, financing, investment and business development partnerships.
Health Technology Insights: Mirvie RNA Platform First to Uncover Unique Molecular Signal for Babies at Risk
“The quality of both the speakers and company presentations at this year’s Biotech Showcase conference was absolutely outstanding,” said Anna Chrisman, Global Managing Director, EBD Group.
More than 100 speakers shared their expertise and varying perspectives, including:
- Grace Colón, CEO & Co-Founder, Inaya Therapeutics, BIO Executive Committee Member
- Olga Danilchanka, Partner, MRL Ventures Fund, Merck
- Alessandro Falcone, Head, JLABS Singapore, Johnson & Johnson
- Andrei Georgescu, CEO & Co-Founder, Vivodyne
- James Healy, Managing Partner, Sofinnova Investments
- William Ho, CEO, In8bio
- David Jenkins, SVP, Head of External Innovation and Research, Ipsen
- Konstantina Katcheves, SVP, Innovation Medicines Business Development and Acquisitions, Teva Pharmaceuticals
- Adam Pearson, Chief Strategy Officer, Astellas Pharma
- Nabiha Saklayen, CEO & Founder, Cellino Biotech
- Scott Whitaker, President & CEO, AdvaMed
- Alice Zheng, Partner, Foreground Capital
- And members of the media, including Alex Philippidis (GEN), Adam Bluestein (Fast Company), Allison DeAngelis (STAT News), Ron Leuty (San Francisco Business Times), Kyle LaHucik (Endpoints News), and David Ewing Duncan.
Health Technology Insights: Science Exchange Announces New Clinical Development Solution
“I’m encouraged by the very strong enthusiasm and engagement here about the industry’s prospects for 2025, as well as the highly positive feedback from investors and partnering companies about the program and the companies they were able to connect with,” Demy added.
Registered attendees can access recorded program sessions and company presentations on-demand anytime through the partneringONE platform.
Health Technology Insights: The Seventh Annual Medical Genetics Awareness Week Will Be Celebrated March 18-21, 2025
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – businesswire
